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An increased prevalence of malignant lymphoma and of gastric cancer has been
observed in large cohorts of patients with common variable immunodeficiency (CVID),
the most frequently symptomatic primary immunodeficiency. Surveillance strategies for
cancers in CVID should be defined based on epidemiological data. Risks andmortality for
cancers among 455 Italian patients with CVID were compared to cancer incidence data
from the Italian Cancer Registry database. CVID patients showed an increased cancer
incidence for all sites combined (Obs = 133, SIR = 2.4; 95%CI = 1.7–3.5), due to an
excess of non-Hodgkin lymphoma (Obs = 33, SIR = 14.3; 95%CI = 8.4–22.6) and of
gastric cancer (Obs = 25; SIR = 6.4; 95%CI = 3.2–12.5). CVID patients with gastric
cancer and lymphoma had a worse survival in comparison to cancer-free CVID (HR:
4.8, 95%CI: 4.2–44.4 and HR: 4.2, 95%CI: 2.8–44.4). Similar to what observed in other
series, CVID-associated lymphomas were more likely to be of B cell origin and often
occurred at extra-nodal sites. We collected the largest case-series of gastric cancers
in CVID subjects. In contrast to other reports, gastric cancer was the leading cause
of death in CVID. Standardized mortality ratio indicated a 10.1-fold excess mortality
among CVID patients with gastric cancer. CVID developed gastric cancer 15 years
earlier than the normative population, but they had a similar overall survival. Only CVID
diagnosed at early stage gastric cancer survived >24 months. Stomach histology from
upper endoscopy performed before cancer onset showed areas of atrophic gastritis,
intestinal metaplasia or dysplasia. CVID patients might progress rapidly to an advanced
cancer stage as shown by patients developing a III-IV stage gastric cancer within 1
year from an endoscopy without signs of dysplasia. Based on high rate of mortality
due to gastric cancer in Italian CVID patients, we hereby suggest a strategy aimed at
early diagnosis, based on regular upper endoscopy and on Helicobacter pylori infection
treatment, recommending an implementation of national guidelines.
Keywords: common variable immunodeficiency: cancer, gastric cancer, lymphoma, IgA, upper endoscopy, risk,
guidelines
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INTRODUCTION
Inherited conditions affecting immune system function are
classified as primary immune deficiencies (PID) (1). As the
PID life expectancy increased because of improvements in
the surveillance, prevention, and treatment, the occurrence
of cancer increased (2, 3). In PID, hematological and non-
hematological malignancies occur mainly in the fourth to the
seventh decades of life while rare case of malignancies are
commonly observed in the pediatric population (4). Among
PID, an increased prevalence of cancer is recognized in patients
affected by common variable immunodeficiency (CVID), the
most common symptomatic primary antibody defect. In CVID,
the antibody deficiency might derive from decreased diversity of
the naive pool, decreased hyper mutation in memory repertoires,
an unusual clonal expansion of un-mutated B cells, and from a
number of defects in innate and adaptive immune mechanisms
(5). Other than sino-pulmonary infections, CVID patients suffer
from associated clinical conditions, including autoimmune and
inflammatory diseases and neoplasia, mainly lymphoma and
gastric cancer (6, 7). Ten years ago, our group described a higher
prevalence of lymphoma and gastric carcinomas in the Italian
cohort of CVID in comparison to the normative population
(8). Five years later, we confirmed this high prevalence rate
TABLE 1 | Characteristics of 455 CVID patients enrolled in the study.
Characteristics All patients Cancer Cancer-free
AGE INTERVAL—n. (SD)
18-35 years 75 (16.5) 7 (6.0) 68 (20.0)***
36–50 years 142 (31.2) 29 (25.0) 113 (33.3)
51–65 years 150 (32.9) 45(38.8) 105 (31.0)
66–80 years 82 (18.0) 33 (28.5) 49 (14.5)**
>80 years 6 (1.3) 2 (1.7) 4 (1.2)
Sex (female)—n. (%) 235 (51.6) 58 (50.0) 162 (47.8)
Age at CVID diagnosis—mean
(SD)
40.1 (15.4) 45.8 (13.2) 38.8 (15.7)***
SERUM IMMUNOGLOBULIN AT DIAGNOSIS (mg/dL)—MEAN (SD)
IgG 250.3 (172.3) 256.2 (168.6) 248.7 (173.6)
IgA 21.6 (34.2) 19.9 (30.8) 22.1 (35.1)
IgM 25.2 (49.8) 37.0 (89.8) 21.9 (30.4)*
Bronchiectasis 118 (31) 26 (31) 92 (30)
Autoimmunity 130 (28) 27 (28) 103 (29)
Lymphoproliferative 113 (31) 28 (33) 85 (29)
Enteropathy 52 (14) 11 (14) 41 (14)
Time of follow-up
person-year—mean (SD)
11.5 (8.9) 11.8 (8.4) 11.4 (9.2)
Patients with cancer—n. (%) 116 (25.5) – –
Patients with more than one
cancer—n. (%)
18 (4.0) – 18(15.5)
Patients alive at the last follow
up—n. (%)
377 (82.9) 51(44.0) 27 (8.0)
*p < 0.01, **p < 0.001, and ***p < 0.0001 (cancer vs. cancer-free CVID patients).
SD, standard deviation; CVID, common variable immunodeficiency; Ig, immunoglobulin.
Immunoglobulin normal range (adults): IgG 700–1600 mg/dL; IgA 68–400 mg/dL; IgM
40–259 mg/dL.
of lymphoma and gastric carcinomas in a four decades study
showing that 21% of adult CVID patients developed cancers.
We also observed that deaths from cancer occurred in 10.2%, a
percentage double than that reported in a study from a CVID
cohort in New York over the same length of time (2, 9). We
suggested that the discrepancy in cancer survival, between the
two cohorts, might have been due to the high prevalence of
deaths for malignancies other than lymphoma in the Italian
CVID cohort, and to deaths for gastric cancer. The percentage of
patients who died for lymphoma, indeed, was similar in the two
studies.
Herein, we analyzed data on the prevalence of hematological
and non-hematological malignancies, on cancer risk, on
mortality and on survival rate in a cohort of 455 Italian adult
CVID patients compared to normative population. Detailed data
on CVID patients diagnosed with gastric cancer, histopathology
of gastric lesions, cancer outcome and possible associated risk-
factors were reported. Based on the high rate of mortality for
gastric cancer in Italian CVID patients, we highlight the need of
a strategy for an earlier diagnosis and we suggest a new schedule
for gastric endoscopy in CVID patients.
METHODS
Study Design
Data on adult CVID patients (>18 years old), regularly followed
in three University-based PID referral centers located in Central
Italy (Rome), Southern Italy (Naples), and Northern Italy
TABLE 2 | Prevalence of cancer diagnosis in 455 Italian CVID patients.
Cancer diagnosis—n. % All patients
n. 455
Female
n. 235
Male
n. 220
n. % n. % n. %
Non-Hodgkin lymphoma 33 7.3 15 6.4 18 8.2
Gastric cancer 25 5.5 9 3.8 16 7.1
Colorectal cancer 10 2.2 4 1.7 6 2.7
Breast cancer 10 2.2 10 4.3 - -
Thyroid cancer 6 1.3 3 1.3 3 1.3
Hodgkin lymphoma 5 1.1 2 0.9 3 1.3
Large Granular Lymphocytic
Leukemia
5 1.1 3 1.3 2 0.9
Lung cancer 4 0.9 2 0.9 2 0.9
Liver cancer 4 0.9 2 0.9 2 0.9
Uterine cancer, body 4 0.9 4 1.7 – –
Uterine cancer, cervical 3 0.7 3 1.3 – –
Prostatic cancer 3 0.7 – – 3 1.3
Pancreatic cancer 3 0.7 2 0.9 1 0.4
Other blood cancer (CML,
polycythemia vera)
3 0.7 1 0.4 2 0.9
Kaposi sarcoma 1 0.2 0 – 1 0.4
Others* 13 3.5 7 3.0 6 2.7
*Others: Bladder cancer, meningioma, melanoma, neuro-endocrine carcinoma, ocular
carcinoma, kidney carcinoma, adrenal carcinoma.
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FIGURE 1 | Cancers diagnosis and death for cancer in CVID and in the normative population. Data related to the proportion of the five most frequently diagnosed
cancers in male and female CVID patients (dashed bars) are shown in comparison to the normative population (IT, white bars) (A). Proportion of deaths for cancer in
male and female CVID patients (dashed bars) are shown in comparison to the normative population (IT, white bars) (B). In CVID, NHL and gastric cancer were the
most commonly diagnosed cancers in both sexes, whereas breast cancer and prostate cancer were the most frequently recorded malignancies in Italian normative
population. Gastric cancer was the first cause of death for cancer in CVID females and males, followed by NHL; breast and lung cancers were the most common
cause of death for cancer in normative population. Data of normative population referred to 2017 AIRTUM report. NHL, non-Hodgkin lymphoma. *p < 0.01;
***p < 0.0001.
(Padua-Treviso) were prospectively collected from 01/01/2001
to 31/12/2017 and retrospectively collected from 01/01/1993
to 31/12/2000. To be considered for analysis, subjects needed
to fulfill the 2016 ESID revised criteria (http://esid.org/
Working-Parties/Registry/Diagnosis-criteria). A set of variables
was recorded for each patient including: gender, date of
birth, date of CVID diagnosis, data on cancer diagnosis and
histology, date of last follow up visit, vital status information,
date and cause of death, CVID-associated diseases (infections,
cancer, autoimmunity, unexplained persistent proliferation, and
unexplained persistent enteropathy) and Helicobacter pylori
(H. pylori) status. We excluded from the analysis patients
whose data on date cancer occurrence and its outcome and
on date of cancer diagnosis, death and last follow-up were
lacking. The follow-up period before the occurrence of cancer
was calculated since the year of immunodeficiency onset. All
subjects were followed until date of death or date of the end
of the study (31 December 2017). For the subset of patients
who developed cancer, medical records were traced to verify
cancer diagnosis, treatments received, clinical complications, and
outcome.
AIRTUM Estimated Cancer Incidence
The Associazione Italiana Registro Tumori (AIRTUM)
(www.registri-tumori.it) is a coordinated system of population-
based cancer registries that collects cancer incidence and survival
data from 20 geographic areas throughout Italy, covering 70%
of the Italian population (without age restriction). Detailed
information is available at http://www.registri-tumori.it/. We
used AIRTUM published data to estimate the expected incidence
of cancer. Among skin malignancies, melanoma was the only
one cancer with data on incidence and mortality reported in the
AIRTUM database. For this reason, we did not collected data for
not-malignant skin cancer.
Statistical Analysis
Demographics of the CVID database were summarized with
descriptive statistics. Sociodemographic and clinical variables
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TABLE 3 | Observed (Obs) and Expected (Exp) numbers and Standardized
Incidence Ratio (SIR) of cancer among 455 Italian patients with CVID.
Obs Exp SIR 95%CI
CANCER
All malignant neoplasms 133 55.1 2.4 1.7–3.5
Non-Hodgkin lymphoma 33 2.3 14.3 8.4–22.6
Gastric cancer 25 3.9 6.4 3.2–12.5
Colorectal cancer 10 8.2 1.2 0.0–1.9
Breast cancer 10 10 1 0.7–1.2
Thyroid cancer 5 1.7 2.9 0.0–6.4
Hodgkin Disease 5 0.4 12.5 3.4–22.4
Lung cancer 4 28 0.1 0.2–0.7
Liver cancer 4 2.1 1.9 0.3–5.6
Uterine cancer, body 4 1.2 3.3 0.1–6.5
Uterine cancer, cervical 3 1.2 2.5 0.1–4.8
Prostatic cancer 3 7.1 0.4 0.1–1.0
Pancreatic cancer 3 1.9 1.6 0.3–3.9
TABLE 4 | Cause of death in CVID patients.
Causes of death n. %
Cancer 47 60.3
Gastric cancer 16 20.5
Non-Hodgkin Lymphoma 14 17.9
Colorectal cancer 6 7.7
Liver cancer 4 5.1
Pancreatic cancer 2 2.6
Breast cancer 2 2.6
Hodgkin Disease 1 1.3
Lung cancer 1 1.3
Uterine cancer 1 1.3
Infections 15 19.2
LRTI (respiratory failure) 12 10.3
Other infections (sepsis, CMV) 3 10.3
Cardiovascular disease 5 6.4
Autoimmune manifestations: AHA, AIH 4 5.1
Others* 7 9.0
Total 78 –
LRTI, lower respiratory tract infections; AHA, autoimmune hemolytic anemia; AIH,
autoimmune hepatitis.
*Parkinson disease, cirrhosis, accident, suicide.
were compared between the patients who developed cancer and
cancer-free patients. Statistical analysis was performed using
frequency distributions. The X2 test was used for categorical
variables and the t-test was used for continuous variables. The
observed numbers of cancer cases among CVID were compared
with the expected numbers calculated based on AIRTUM data
on incidence rates of cancer in 5-year interval to yield the
standardized incidence ratio (SIR). “All cancer” and site-specific
cancer SIRs were calculated for the entire cohort, and separately
for men and women. For mortality analysis, the time since
diagnosis was determined using the age at the time of CVID
diagnosis or the age at birth. The endpoint used was the time
of last known follow-up or the date of death. Probabilities of
survival after the diagnosis of CVID and after the diagnosis of
cancer were estimated from Kaplan Meier life Table. Mortality
rates (crude death rates, CDRs) of the general population
were used to calculate the standardized mortality ratio (SMRs).
The CDR was obtained from AIRTUM. SMRs were calculated
using the formula, SMR = Observed (Obs) deaths/expected
(Exp) deaths. We calculated SMRs as incident cases divided
by the contributed person-years. However, general population
incidence and mortality data for Italy before 2003 were not
available, so only cancer and death occurred after 2003 were
included in the analysis. Statistical Package for Social Sciences
version 15 (SPSS Inc., 233 South Wacker Drive, 11th Floor,
Chicago) was used for the analysis. Confidence Intervals (CI95%)
were calculated by R-3.4.4 version.
RESULTS
Patients
As of 31 December 2017, 501 subjects with a CVID diagnosis
were included in the dataset. We excluded from the analysis 46
subjects who did not satisfy ESID criteria and patients whose date
of death, date of cancer occurrence and outcome, and date of last
follow-up could not be accurately determined. Data on 455 CIVD
patients were included in the analysis. The characteristics of
CVID patients enrolled in the study are summarized in Table 1.
The mean age at last follow-up was 51.1 ± 15.0 years, with a 1:1
female: male ratio. Patients were followed-up for a cumulative
period of 5,169 person-years with a mean time of follow-up of
11.5± 8.9 years.H. pylori status was available in 325/455 patients.
H. pylori infection by histology was found in 40 patients (12%).
Cancer Prevalence and Risk in CVID
Patients
During the study time, 132 separate cancers were diagnosed in
116 patients (25.5%). Eighteen patients (4%) developed more
than one cancer. The age at CVID onset was higher for patients
who developed cancer in comparison to those who did not (45.9
± 13.2 vs. 38.1 ± 15.7 yrs, p < 0.0001, Table 1). The mean
age at the first cancer diagnosis was 52.5 ± 13.8 (range: 26–
85 yrs). Sixty-seven cancers were diagnosed in women and 65
cancers in men. Malignancies diagnosed were: lymphoma (38;
29%), gastrointestinal cancers (35; 26%), genitourinary cancers
(14; 8%), breast cancers (10; 7%), uterine cancers (7; 5.3%),
thyroid cancers (6; 4%), lung cancers (4; 3%), liver cancers (4;
3%), prostatic cancer (3; 2%), and pancreatic cancer (3; 2%).
The overall and sex-related prevalence of single cancer was
summarized in Table 2.
Figures 1A,B showed the percentage of the top five diagnosed
cancers and the top five fatal cancers seen in CVID in
comparison to the normative Italian population. The most
common malignancy diagnosed in the AIRTUM database was
breast cancer (women only), prostate cancer (men only), lung,
and colorectal cancers. The incidence of these cancers was not
increased in CVID patients in comparison to the AIRTUM
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FIGURE 2 | CVID survival. Survival in female (A) and male (B) CVID participants: data were shown as overall survival (black dashed line), in CVID patients with gastric
cancer (black bold line), in patients with lymphoma (black line) and in cancer-free CVID patients (gray dashed line). No survival differences were observed between
females and males; CVID subjects with gastric cancer or lymphoma had a worse survival in comparison to cancer-free CVID population.
TABLE 5 | Standardized mortality ratios (SMRs) for cancers causing death in
CVID.
Cancers Obs Exp SMR 95%CI
All malignant neoplasm 47 44.5 1.0 0.5–1.6
Gastric cancer 16 2.0 10.1 3.8–16.3
Non-Hodgkin lymphoma 14 0.8 16.5 8.8–31.4
Colorectal cancer 6 2.1 2.8 0.1–6.3
Liver cancer 4 1.8 2.9 0.1–5.9
Pancreatic cancer 2 1.7 1.2 0.6–3.2
Breast cancer 2 7.0 0.3 0.0–0.5
Hodgkin Disease 1 0.1 10.0 0.0–45.2
Lung cancer 1 6.6 0.1 0.3–0.5
Uterine cancer 1 0.3 2.8 0.0–8.3
database (Table 3). Ten female CVID patients were diagnosed
with breast cancer (Exp: 10.0; SIR: 1.0; 95%CI: 0.7–1.2). Three
male CVID patients were diagnosed with prostate cancer (Exp:
7.1; SIR: 0.4, 95%CI: 0.1–1.0). There was no increase in the rates
of lung cancer (Obs: 4, Exp: 28.0, SIR 0.1; 95%CI: 0.2–0.7) and
colon cancer (Obs: 10; Exp: 8.2; SIR 1.2; 95%CI: 0.0–1.9) among
CVID patients vs. normative population (Table 3). In contrast
to Italian normative population, the most commonly diagnosed
malignancies in female and male subjects with CVID were non-
Hodgkin lymphoma (NHL) and gastric cancer (Figure 1A). The
risk for NHL and Hodgkin’s lymphoma (HD) was increased
by 14.3- and 12.5-fold, respectively, based on 33 and 5 cases
observed. The risk for gastric cancer was increased 6.4-fold based
on 25 cases observed (Table 3).
Survival and Mortality
Three-hundred and seventy-four (82.4%) patients were alive at
the end of the study-time. During the study time, we observed
78 deaths in the patient population. Malignancies were the first
cause of death, accounting for 60.3% of deaths. Gastric cancer
was the leading cause of death (20.5%). Infections accounted for
19.2% of deaths, 80% due to lower tract respiratory infections.
Causes of mortality in patients are detailed in Table 4. The CVID
overall survival (OS) was 85.1% (SE 2.3%) at 60 years and 61.8%
(SE 4.2%) at 70 years. No differences were observed between
males and females. Cancer-free CVID had a better survival in
comparison to those with gastric cancer (Log-Rank p < 0.0001,
HR: 4.8, 95%CI: 4.2–44.4, Figure 2A) and lymphomas (Log-Rank
p= 0.001, HR: 4.2, 95%CI: 2.8–44.4, Figure 2B).
Cancer excess of mortality was expressed as SMRs (Table 5).
The most fatal cancers in the AIRTUM database were lung,
colorectal and breast cancer. We found no significant increase
in the mortality for colorectal cancer (Obs: 6; Exp: 2.1; SMR: 2.8,
95%CI: 0.1–6.3) and a significant lower mortality for lung and
breast cancers in CVID patients (lung cancer: Obs: 1; Exp: 6.6;
SMR: 0.1; 95%CI: 0.3–0.5; breast cancer: Obs; 2; Exp: 7.0; SMR:
0.3; 95%CI: 0.0–0.5, Table 5). Moreover, in CVID we found an
excess of mortality for NHL (Obs: 14; Exp: 0.8; SMR: 16.5; 95%CI:
8.8–31.4) and gastric cancer (Obs: 16; Exp: 2.0; SMR: 10.1; 95%CI:
3.8–16.3) (Table 5).
Gastric Cancer
Gastric cancer was the second most frequent cancer diagnosed
in CVID accounting for 18.9% of cancer diagnosed, and the
first cause of death. Of the 25 cases of gastric cancer, 16 (64%)
occurred in men. The age at cancer diagnosis was 51.8 ± 13.7
years (range: 30–75), 15 years younger than that reported in
the Italian population (10). The diagnosis of cancer occurred
within 10 years from the CVID diagnosis in two thirds of these
patients. CVID subjects with gastric cancer had a similar age at
immunodeficiency onset than the entire CVID cohort (40.0 ±
15.0 vs.39.9 ± 15.4, p = 0.975). Undetectable IgA (<7 mg/dL)
and IgM (<6 mg/dL) serum levels at time of CVID diagnosis
were more likely in patients with gastric cancer in comparison
to those without that complication (IgA: OR 27.5, 95%CI: 1.5–
475.9, p = 0.027; IgM: OR 7.4, 95% CI: 1.5–36.1, p = 0.013).
Seven out of 25 patients had an additional malignancy: three
patients were diagnosed with lymphoma, two with colorectal
cancer, one with gallbladder cancer, and one withmeningioma. In
addition, two patients had a multifocal gastric adenocarcinoma
treated by two-stage gastrectomy (Table 6). One patient (n. 1)
Frontiers in Immunology | www.frontiersin.org 5 November 2018 | Volume 9 | Article 2546
Pulvirenti et al. Cancers in CVID
TABLE 6 | Age at PID and at cancer diagnosis, survival, outcome, histology, cancer stage, and cancer treatment in 25 CVID patients with gastric cancer.
ID Sex Age at PID
diagnosis
(years)
Age at cancer
diagnosis
(years)
Survival after
cancer diagnosis
(months)
Outcome Histology Stage Treatment Additional
cancer
Enteropathy
(before cancer
diagnosis)
1 M 39 40 408 Alive Early gastric cancer,
pT1N0 G1
stage I Gastrectomy
(total)
Kaposi sarcoma,
colorectal
carcinoma
No
2 F 25 31 12 Deceased
(cancer)
Gastric adenocarcinoma,
NOS
NA Chemotherapy,
NOS
No Yes
3 F 45 45 252 Alive Gastric adenocarcinoma,
NOS
NA Gastrectomy,
NOS
Meningioma No
4 F 67 69 120 Deceased
(cancer)
Early gastric cancer
pT1N0 G2,
stage I Gastrectomy
(total)
Biliary tract
carcinoma
NA
5 M 40 49 7 Deceased
(cancer)
Gastric adenocarcinoma,
NOS
NA Gastrectomy
(total)
No Yes
6 M 27 51 204 Alive Gastric adenocarcinoma,
intestinal type
pT1N0 G2
stage I Gastrectomy
(total)
NHL
(duodenal)
lymphoma
No
7 M 58 74 36 Deceased
(cancer)
Gastric adenocarcinoma,
intestinal type,
PT1, N0, M0
stage IA Gastrectomy
(subtotal)
No Yes
8 F 35 45 144 Alive Gastric adenocarcinoma,
NOS pT1bN1 G1
stage IB Gastrectomy
(subtotal)
No No
9 M 67 67 132 Alive Gastric adenocarcinoma,
NOS
Gastrectomy
(subtotal)
Colorectal
carcinoma
Yes
10 F 32 38 132 Alive Early gastric cancer,
pT1N0 G2
stage I Gastrectomy
(subtotal)
HD Yes
11 M 64 67 30 Deceased
(cancer)
Gastric adenocarcinoma,
intestinal type,
PT1, N0, Mx, G3
stage I Gastrectomy
(subtotal),
Chemotherapy
(lederfolin,
xeloda,
5-fluorouracil)
No Yes
12 M 69 75 24 Deceased
(cancer)
Gastric adenocarcinoma,
NOS
NA Supportive No Yes
13 F 35 68 12 Deceased
(cancer)
Gastric Adenocarcinoma,
G3
NA Supportive NHL Yes
14 F 27 38 9 Deceased
(cancer)
Gastric adenocarcinoma,
NOS
NA Supportive No NA
15 M 30 47 12 Deceased
(cancer)
Gastric adenocarcinoma,
NOS
stage IIIB Chemotherapy,
NOS
No Yes
16 M 40 40 84 Alive Multifocal Gastric
Adenocarcinoma
pT2bN0 G3 CMV+
stage IB Gastrectomy
(total, two-step)
No No
17 M 59 68 12 Deceased
(cancer)
Gastric adenocarcinoma,
NOS
NA Supportive No Yes
18 M 36 48 11 Deceased
(respiratory
failure)
Gastric adenocarcinoma,
NOS
NA Chemotherapy,
NOS
No NA
19 M 18 40 15 Deceased
(cancer)
Gastric adenocarcinoma,
intestinal type
pT3N3bMx G3
stage IIIC Gastrectomy
(total),
Chemotherapy
(platinum/5-
fluorouracil)
No Yes
20 F 43 64 24 Deceased
(cachexia,
meningitis)
Gastric adenocarcinoma,
intestinal type pT3N2 G3
stage IIIA Gastrectomy
(subtotal), +
Capecitabine
No No
21 M 22 30 8 Deceased
(cancer)
Gastric adenocarcinoma,
NOS
stage IV Supportive No No
(Continued)
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TABLE 6 | Continued
ID Sex Age at PID
diagnosis
(years)
Age at cancer
diagnosis
(years)
Survival after
cancer diagnosis
(months)
Outcome Histology Stage Treatment Additional
cancer
Enteropathy
(before cancer
diagnosis)
22 M 29 40 7 Deceased
(cancer)
Gastric adenocarcinoma,
NOS
stage IV Chemotherapy,
NOS
No Yes
23 M 49 51 15 Alive Multifocal gastric
adenocarcinoma,
intestinal type,
pT1pN0 G3
stage I Gastrectomy
(total, two-step)
No No
24 M 47 50 14 Alive Early gastric cancer,
intestinal type,
pT1bNx G3
stage I Gastrectomy No No
25 F 46 59 6 Deceased
(cancer)
Gastric adenocarcinoma
G3
stage IV Chemotherapy
(epirubicine,
platinum,
5-fluorouracil)
No Yes
NOS, not otherwise specified; NA, not available M, Males, F, Females; NHL, Non-Hodgkin lymphoma; HD, Hodgkin disease.
had a positive family history for gastric cancer: three relatives,
including his IgA-deficient brother, developed the malignancy.
In these two brothers, mutations of CDH1 gene were not found.
Fifteen patients with gastric cancer died during the study time.
Overall, the average SMR indicated a 10.1-fold excess mortality
among CVID patients with gastric cancer. The 10-year survival
probability of the entire cohort of patients with gastric cancer was
25%. Clinical staging was available for 16/25 patients. Patients
classified as stage I had a better survival in comparison to
those with stage III-IV (HR: 0.01, 95%CI: 0.0–0.1, p < 0.0001,
Figure 3). H. pylori status and histology of gastric endoscopic
biopsies collected before the diagnosis of cancer was available
for 7 patients (Table 7): areas of dysplasia were identified in
two subjects whereas areas of atrophic gastritis and/or intestinal
metaplasia were found in all patients. In the two patients with
dysplasia, the following endoscopy revealed a stage I malignancy,
6 months apart (patient n. 23). Patient n. 25 agreed to undergo
a further gastroscopy only 15 months apart, which allowed
diagnosis of a stage IV gastric cancer. Interesting to note, patient
n. 20 and n. 22 developed a high-grade gastric cancer <14
months after the preceding endoscopy whose histology did not
show any signs of dysplasia. At least one H. pylori detection was
significantly related to gastric cancer (43 vs. 13%, OR: 5.3, 95%CI:
1.1–24.8, p= 0.042).
Lymphoma
Lymphoma was the most frequent cancer diagnosed in CVID
and the second cause of death for cancer (Tables 2, 4). The age
at lymphoma diagnosis was 32.8 ± 4.6 years for HD and 52.4
± 13.1 years for NHL. The age at CVID diagnosis was higher
in patients with lymphoma in comparison to those without
lymphoma (45.7± 12.4 vs. 39.6± 15.6, p= 0.008). Three patients
first presented with lymphoma prior to CVID diagnosis, raising
the question if hypogammaglobulinemia might be secondary to
the lymphoproliferative disease (Table 8). However, the longtime
state of antibody defect after the diagnosis and treatment of
lymphoma might suggest this possibility. As widely described
(2–9, 11), also in our cohort, CVID-associated lymphoma was
more likely to be of B cell origin (88.4%) with a predominance
of NHL (81.8%). T-cell lymphomas (peripheral T-cell lymphoma,
angio-immunoblastic T-cell lymphoma and anaplastic T-cell
lymphoma) and one primitive effusion cavity (PEL) lymphoma
were also observed (Table 8). Similar to what observed in other
series of CVID patients about 30% were extra-nodal lymphomas.
Patients with lymphoma were more likely to have lymphopenia
(lymphocytes < 1,000 cell/mm3) (OR: 3.0, 95%CI: 1.1–8.3,
p = 0.030) and polyclonal lymphocytic infiltration phenotype
(OR: 2.7, 95%CI: 1.2–6.3, p= 0.016) before cancer diagnosis.
DISCUSSION
This longitudinal study on a large cohort of CVID patients over a
cumulative period of 5,169 person-years showed that one fourth
of patients developed a malignancy. Cancer represents the first
cause of death in our patient’s population. The most commonly
diagnosed malignancies in CVID were NHL and the first cause of
death was gastric cancer. The excess of mortality for lymphoma
and gastric carcinoma in CVID was increased by more than
10-fold in comparison to normative population. Several studies
reported a high frequency of malignancies in CVID patients
(2, 3, 6–9, 11–14) with a prevalence ranging from 1.5 to
20.7%. However, only few studies provided SIR, allowing the
comparison of data on CVID to data on normative population.
These surveys showed an excess of incidence ranging from 4-
to 30-fold for NHL and from 3- to 47-fold for gastric cancer
(3, 6, 7, 15). Nevertheless, the prevalence other malignancies was
not increased, confirming that patients with antibody deficiencies
have a narrow range of cancers (6).
Lymphoma is considered as one of the more severe
complications of CVID. The prevalence registered in our
cohort was similar to that found across the different countries
examined (2–9, 11, 12). The histological types reported in
the different series of CVID-associated lymphoma were also
similar to our findings, with a predominance of non-Hodgkin
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FIGURE 3 | Gastric cancer survival by sex and staging. Survival in the cancer free CVID subjects (black bold line) and in CVID females (gray dashed line) and males
(gray line) with gastric cancer was shown in (A). Survival in patients scored as stage I (gray line) and in patients scored as stage III-IV (dashed line) was shown in
(B). No difference was observed between CVID females and males with gastric cancer; patients scored as stage I had a better survival in comparison to patients
scored as stage III-IV.
TABLE 7 | H. pylori status and histology of gastric biopsies from the endoscopy preceding the examination leading to gastric cancer diagnosis in seven CVID patients.
ID H. pylori
(pos/neg)
Histology of biopsy taken at the endoscopy preceding
the one with gastric cancer diagnosis
Interval between
endoscopies (months)
Stage at cancer diagnosis Outcome
9 pos Active chronic gastritis, intestinal metaplasia 36 NA Alive
12 neg Atrophic gastritis 35 NA Death
13 pos Atrophic gastritis 12 NA Death
20 neg Active chronic gastritis (moderate) with incomplete intestinal
metaplasia
14 Stage IIIA Death
22 pos Active chronic gastritis (moderate), intestinal metaplasia 14 Stage IV Death
23 neg Atrophic gastritis, high grade dysplasia 6 Stage I Alive
25 neg Intestinal metaplasia, high-grade dysplasia 15 Stage IV Death
NA, not available.
B cell lymphomas, possibly occurring at extra nodal sites. We
confirmed the observation by Chapel et al. showing that CVID
patients with polyclonal lymphadenopathy phenotype have an
increased risk of lymphoid malignancy that generally occurs late
in the disease course (16). In addition, we found that CVID
patients with lymphopenia had a 3-fold increased risk to develop
lymphomas. In CVID patients, diagnosis of lymphoma may be
particularly challenging. Immune-histochemical analysis, studies
on clonality andmolecular studies might be helpful to distinguish
reactive from neoplastic lymphoproliferative diseases, even if
CVID patients with clonal B cell expansion, who survive without
developing an overt lymphoma, have been described (12, 17).
Treatment of CVID-associated lymphoma was usually like the
treatment of lymphoma in other settings and usually it included
rituximab.
Herein, to the best of our knowledge, we collected the largest
case-series of gastric cancers in CVID subjects ever described,
showing a high prevalence and an excess of mortality for gastric
cancer. However, the SIR for gastric cancer was similar to that
found across other studies providing this kind of figure (3, 6, 7).
This difference might be related to the observation that gastric
cancer prevalence may vary significantly within and between
countries (18). In comparison to the normative population,
CVID patients were on the average 15-years younger at the time
of cancer onset. As reported for non-CVID subjects (19), CVID
patients with early-stages gastric cancer had a better prognosis
in comparison to those with more advanced stage, who died
within 2 years since cancer diagnosis. According to our data,
chronic atrophic gastritis and extensive intestinal metaplasia are
invariably associated with gastric cancer in CVID. Similarly,
De Petris et al. (20) showed that these adenocarcinomas were
diagnosed at a young age and were of intestinal type. They
were also associated with increased numbers of intra-tumoral
lymphocytes, paucity of plasma cells and nodular lymphoid
hyperplasia, all features suggestive of chronic inflammation of the
gastric mucosa.
These observations gave us the chance to suggest the
implementation of current screening strategy, aimed to an early
diagnosis. The appropriate timing of upper endoscopy in CVID
is a matter of debate. In the general population, Rugge et al.
suggested performing upper endoscopy every 2 years in subjects
with gastritis scored as stage III–IV (10). In CVID, Dhalla et al.
(21) suggested to perform upper endoscopy in patients with
risk factors for gastric cancer (H. pylori positivity, low serum
vitamin B12 and iron concentrations) with an interval between
the subsequent endoscopic assessment based on histological
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TABLE 8 | Characteristics of CVID patients diagnosed with lymphoma.
ID Sex Age at cancer onset,
years
Age at CVID
diagnosis,
years
Survival
after cancer,
months
Outcome
(cause)
Histology and stage Treatment Additional cancer
6 M 50 37 216 Alive Diffuse large B cell
lymphoma (small bowel)
Chemotherapy NOS Gastric cancer
10 F 32 42 336 Alive HD CHOP, ABV Gastric cancer
13 F 67 35 12 Deceased
(gastric cancer)
Diffuse large B cell
lymphoma
NA Gastric cancer
26 F 47 47 8 Deceased
(lymphoma)
NHL not further classified NA No
27 M 38 37 120 Alive Diffuse large B cell
lymphoma of small bowel,
stage IVE
R-CHOP No
28 F 50 44 13 Deceased
(lymphoma)
T-cell lymphoma (peripheral
T cell lymphoma)
CHOP, autologous
HSCT, Brentuximab
No
29 F 64 58 12 Deceased
(lymphoma)
T-cell lymphoma
(angioimmunoblastic T cell
lymphoma)
Prednisone No
30 M 40 47 144 Deceased
(lymphoma)
NHL not further classified NA No
31 M 48 41 132 Alive NHL not further classified NA No
32 F 74 47 24 Alive Diffuse large B cell
lymphoma (large bowel)
R-CHOP, RTX No
33 M 53 47 9 Alive Diffuse large B cell
lymphoma (T-cells rich)
R-CHOP No
34 M 29 30 14 Alive Diffuse large B cell
lymphoma
R-CHOP No
35 M 58 55 36 Alive NHL not further classified Chemotherapy NOS No
36 M 59 35 12 Deceased
(lymphoma)
Cutaneous diffuse large B
cell lymphoma leg-type
R-CHOP, radiotherapy No
37 F 67 43 84 Alive Marginal Zone Lymphoma
(Splenic)
Splenectomy Lung cancer
38 M 54 47 84 Alive NHL not further classified NA No
39 F 29 28 24 Alive Lymphoplasmacytic
lymphoma
Chemotherapy NOS No
40 M 47 45 6 Deceased
(lymphoma)
NHL not further classified NA No
41 F 65 62 8 Deceased
(lymphoma)
Diffuse large B cell
lymphoma
NA No
42 F 62 56 12 Alive Marginal Zone Lymphoma
(nodal and extra nodal)
RTX, bendamustine No
43 M 60 60 36 Alive Marginal Zone Lymphoma
(nodal and extra nodal)
R-CHOP No
44 M 47 47 72 Alive Anaplastic T cell Lymphoma
ALK- stage IVB (skin)
CHOEP, FEAM and
autologous HSCT
No
45 F 67 64 11 Deceased
(lymphoma)
NHL not further classified NA No
46 F 61 70 168 Deceased
(cardiovascular)
Diffuse large B cell
lymphoma (small bowel)
Ileocecal resection +
R-CHOP
No
47 F 41 38 24 Alive Marginal Zone Lymphoma NA No
48 M 52 56 120 Alive NHL, not further classified,
stage IV
R-FN, R-CHOP No
49 M 70 59 12 Alive Marginal Zone Lymphoma
(nodal, indolent behavior)
Rituximab +
bendamustine
Prostatic cancer
50 M 41 40 15 Alive Kaposi sarcoma/Primitive
effusion lymphoma,
HHV8+/EBV+
CDE No
(Continued)
Frontiers in Immunology | www.frontiersin.org 9 November 2018 | Volume 9 | Article 2546
Pulvirenti et al. Cancers in CVID
TABLE 8 | Continued
ID Sex Age at cancer onset,
years
Age at CVID
diagnosis,
years
Survival
after cancer,
months
Outcome
(cause)
Histology and stage Treatment Additional cancer
51 F 74 62 72 Alive MALT Lymphoma (gastric) NA No
52 M 59 59 60 Deceased
(lymphoma)
Diffuse large B cell
lymphoma (lung), stage IVB
R-CHOP, R-COMP No
53 F 45 54 216 Deceased
(lymphoma)
NHL not further classified
(low grade)
R-CHOP + Etoposide Uterine cancer, body
54 M 55 55 10 Deceased
(lymphoma)
NHL not further classified NA No
55 M 36 21 108 Alive HD, classic type, stage IIIsB ABVD No
56 M 30 28 12 Deceased
(lymphoma)
HD, classical type,
lymphocyte-depleted, stage
IV
Chemotherapy NOS Thyroid cancer
57 F 28 38 12 Deceased
(T-cell
lymphoma)
HD, mixed-cellularity type Radiotherapy Thyroid cancer,
angio-immunoblastic
T cell lymphoma)
58 M 29 18 8 Alive HD, sclero-nodular type ABVD, radiotherapy No
59 M 39 38 96 Deceased
(lymphoma)
HD, classical type, stage IVA VEBEP, HSCT No
ABV, Adriamycin, Hydroxydaunorubicin, Bleomycin, Vinblastine; ABVD, Adriamycin, Hydroxydaunorubicin, Bleomycin, Vinblastine, Dacarbazine; CHOEP, Cyclophosphamide,
Doxorubicin, Etoposide, Vincristine, Prednisone; CHOP, Cyclophosphamide, Hydroxydaunorubicin, Vincristine, Prednisone; CDE, Cyclophosphamide, Doxorubicin, Etoposide; COPP,
Cyclophosphamide, Vincristine, Procarbazine, Prednisone; FEAM, Fotemustine, Etoposide, Cytarabine, Melphalan; R-CHOP, Rituximab, Cyclophosphamide, Hydroxydaunorubicin,
Vincristine, Prednisone; FN-R, Rituximab, Fludarabine, Mitoxantrone; HD, Hodgkin disease, NHL, Non-Hodgkin lymphoma, HSCT, Hematopoietic stem cell transplantation; R-COMP,
Rituximab, Cyclophosphamide, Vincristine, Myocet, Prednisone; RTX, Rituximab; VEBEP, Etoposide, Epirubucin, Bleomycin, Cyclophosphamide, Prednisolone; NOS, not otherwise
specified; NA, not available.
findings: every 1–3 years in CVID patients with metaplasia,
every 3 years in patients with atrophic gastritis, and every 6–
12 months in those with dysplasia. However, this interval may
not be suitable for CVID, who rapidly develop advanced-stage
cancer with poor prognosis. In fact, we showed that some CVID
developed a high-grade gastric cancer already 12–14months after
an endoscopy showing no histologic signs of dysplasia. This rapid
cancer development in CVID was unexpected since no epithelial
gastric cancer was identified in patients without signs of dysplasia
on a cohort of 1,615 Italian non-CVID followed over a 1–5 years
period (10).
H. pylori eradication represents the main strategy to reduce
the lifetime risk of gastric cancer since H. pylori is widely
recognized as the leading cause of gastric cancer (22). In
CVID, serological tests are not useful to identify H. pylori
positive patients and only direct diagnostic methods for
H. pylori detection should be considered (23). However, follow-
up strategies targeted at gastric cancer secondary prevention
cannot rely only on H. pylori identification, since the eradication
of H. pylori might not abolish the risk for neoplastic progression
(24–26). This is supported by our observation in two CVID
patients who developed gastric cancer 1–2 years after aH. pylori-
negative gastric biopsy.
On the basis of our data, we recommend the implementation
of national guidelines based on regular upper endoscopy and
on treatment of H. pylori infection. We propose to always
perform upper endoscopy at the time of CVID diagnosis; to
repeat endoscopy every 24 months in patients with normal
histology; every 12 months in patients with atrophic gastritis
or intestinal metaplasia, and every 6 months in patients with
dysplastic lesions. Diagnosis of H. pylori infection should be
actively ruled out at diagnosis and during the course of CVID
disease. The prevalence and the risk of gastric cancer detected
in Italian CVID patients might be related to the epidemiology of
H. pylori infection in our country. Thus, further studies should
be undertaken in other countries before they adopt our suggested
measures of disease management. However, a careful endoscopic
monitoring of gastric cancer should be advisable also in countries
with lowH. pylori prevalence, since the rate of antibiotic-resistant
strains is increasing worldwide (22).
Our study has some limitations. First of all, we included
in the analysis also retrospective data with possible survival
bias. Second, we did not include in the analysis the genetic
diagnoses of the cohort. Since it has been shown the risk of gastric
cancer was not increased among relatives of CVID patients (7),
however, it is possible that cancer morbidity might be related
to the immunodeficiency per se rather than to family habits
or environmental factors, including H. pylori sharing. Finally,
preliminary data suggested spontaneous gastric cancer in models
of NFkappaB1 deficiency (27) and recent papers suggested
that significant proportion of CVID patients may harbor
haploinsufficient NFKB1 mutations (28). Additional studies on
alterations of gastric mucosal immunity and microbiota and on
genetic alterations are needed to better understand the gastric
carcinogenesis in CVID patients.
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